Drugs Made In America Acquisition II (NASDAQ:DMII) Trading 0.1% Higher – What’s Next?

Shares of Drugs Made In America Acquisition II Corp. (NASDAQ:DMII) rose 0.1% during mid-day trading on Friday . The stock traded as high as $9.98 and last traded at $9.97. Approximately 73,659 shares traded hands during trading, a decline of 41% from the average daily volume of 123,897 shares. The stock had previously closed at $9.96.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings began coverage on Drugs Made In America Acquisition II in a research report on Monday, March 2nd. They issued a “sell (e)” rating on the stock. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Drugs Made In America Acquisition II Trading Up 0.1%

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Geode Capital Management LLC purchased a new stake in shares of Drugs Made In America Acquisition II during the fourth quarter valued at approximately $265,000. Virtu Financial LLC purchased a new position in Drugs Made In America Acquisition II in the 4th quarter worth approximately $317,000. ABC Arbitrage SA purchased a new position in Drugs Made In America Acquisition II in the 4th quarter worth approximately $396,000. Deltec Asset Management LLC bought a new position in Drugs Made In America Acquisition II in the 4th quarter valued at approximately $495,000. Finally, Royal Bank of Canada bought a new position in Drugs Made In America Acquisition II in the 4th quarter valued at approximately $655,000.

About Drugs Made In America Acquisition II

Drugs Made In America Acquisition II (NASDAQ:DMII) is a special purpose acquisition company (SPAC) formed to raise capital through a public listing for the purpose of effecting a business combination. As a blank‑check vehicle, the company itself does not operate a traditional commercial business; instead, it seeks to identify, negotiate and complete an acquisition, merger, share exchange, asset purchase or similar business transaction with one or more target companies.

The stated investment focus reflected in the company’s name indicates an emphasis on the pharmaceutical and life sciences sector, with a particular interest in domestic drug manufacturing, supply‑chain resiliency and related healthcare operations in the United States.